Affiliation: New York University
- Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeksJudith A Aberg
Bellevue Hospital Center at New York University School of Medicine, New York, USA
AIDS Res Hum Retroviruses 28:1184-95. 2012..This first pilot comparison in HIV-1-infected subjects suggests that DRV/r has a metabolic profile similar to ATV/r over 48 weeks of treatment. Further randomized studies are warranted...
- Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of AmericaJudith A Aberg
AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York 10016, USA
Clin Infect Dis 39:609-29. 2004
- Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108Judith A Aberg
New York University, New York, New York, USA
AIDS 20:725-9. 2006..Nelfinavir, an HIV protease inhibitor with numerous drug-drug interactions, is associated with dyslipidemia. Pravastatin is the preferred statin prescribed for HIV-associated dyslipidemia...
- A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087Judith A Aberg
AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York, New York 10016, USA
AIDS Res Hum Retroviruses 21:757-67. 2005..Combination therapy with fenofibrate and pravastatin for HIV-related dyslipidemia provides substantial improvements in lipid parameters and appears safe, but is unlikely to achieve all NCEP targets for lipid levels...
- The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infectionMartin Markowitz
Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University, New York, New York, USA
J Infect Dis 201:1298-302. 2010..Adjunctive therapy with cyclosporine in this setting does not provide apparent virologic or immunologic benefit...
- Neuropsychiatric complications of antiretroviral therapyMichelle S Cespedes
Division of Infectious Disease, Department of Medicine, New York University School of Medicine, New York, New York 10016, USA
Drug Saf 29:865-74. 2006..Our intent is to present practitioners with data that can be used in a practical way to both educate and improve outcomes in the HIV-infected patient population...
- Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trialScott M Hammer
Division of Infectious Diseases, Department of Medicien, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
JAMA 288:169-80. 2002..Management of antiretroviral treatment failure in patients receiving protease inhibitor (PI)-containing regimens is a therapeutic challenge...
- Lipid management in patients who have HIV and are receiving HIV therapyJudith A Aberg
Bellevue Hospital Center, AIDS Clinical Trials Unit, New York University School of Medicine, 550 First Avenue, BCD 5 Room 558, NY 10016, USA
Endocrinol Metab Clin North Am 38:207-22. 2009..Evidence for these two strategies is discussed...
- Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockersMarshall J Glesby
Weill Medical College of Cornell University, New York, NY 10021, USA
Clin Pharmacol Ther 78:143-53. 2005..We evaluated potential bidirectional pharmacokinetic interactions between calcium channel blockers and coadministered indinavir and ritonavir...
- Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomesDouglas A Jabs
Department of Ophthalmology, The Mount Sinai School of Medicine, New York, New York, USA
Ophthalmology 117:2152-61.e1-2. 2010..To describe the 5-year outcomes of patients with cytomegalovirus (CMV) retinitis and AIDS in the era of highly active antiretroviral therapy (HAART)...
- Implementation of HIV testing at 2 New York City bathhouses: from pilot to clinical serviceDemetre Daskalakis
Division of Infectious Diseases and Immunology, New York University Langone Medical Center, New York, New York 10016, USA
Clin Infect Dis 48:1609-16. 2009..Several cities in the United States have developed programs that offer HIV testing in these venues. Similar programs have not existed before in New York City...
- Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individualsDonald Chen
New York University, Department of Medicine, Division of Infectious Disease, AIDS Clinical Trials Unit, Bellevue C and D Building, Room 558, 550 First Avenue, New York, NY 10016 6481, USA
Expert Rev Anti Infect Ther 5:921-8. 2007..To date, human trials suggest that pafuramidine is well tolerated overall and has clinical activity against Pneumocystis pneumonia. In this article, we review the available data for the use of pafuramidine in Pneumocystis pneumonia...
- Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of AmericaJudith A Aberg
New York University School of Medicine, Bellevue Hospital Center, New York, USA
Clin Infect Dis 49:651-81. 2009..HIV-infected persons should be managed and monitored for all relevant age- and gender-specific health problems. New information based on publications from the period 2003-2008 has been incorporated into this document...
- Cardiovascular complications in HIV management: past, present, and futureJudith A Aberg
AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University School of Medicine, New York, NY 10016, USA
J Acquir Immune Defic Syndr 50:54-64. 2009..These benefits of antiretroviral therapy have been demonstrated in studies comparing the superior efficacy of continuous vs. intermittent HAART...
- A tale of two fungi in a person with HIVJason Faulhaber
Division of Infectious Diseases and Immunology, New York University School of Medicine, New York, NY, USA
MedGenMed 8:2. 2006
- Drug-drug interactions with newer antiretroviral agentsJudith A Aberg
New York University School of Medicine and Bellevue Hospital Center, New York, NY, USA
Top HIV Med 16:146-50. 2008....
- Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapyJudith A Aberg
Department of Medicine, Washington University School of Medicine, AIDS Clinical Trials Unit, St Louis, MO, 63108, USA
Clin Infect Dis 35:E8-E13. 2002..The low rate of these unusual MAC infections does not warrant continuation of primary or secondary prophylaxis after presumed immune reconstitution...
- A case of nocardia osteomyelits--is HIV to blame?Judith A Aberg
Washington University, AIDS Clinical Trials Unit, St Louis, USA
AIDS Read 12:77. 2002
- Coronary heart disease in people infected with HIVCarlos D Malvestutto
New York University Langone Medical Center, New York, USA
Cleve Clin J Med 77:547-56. 2010..As this population ages, cardiovascular disease is becoming an important cause of morbidity and death. The authors of this review discuss the magnitude and likely mechanisms of the risk and strategies for managing it...
- Case files from the Bellevue Hospital Center at New York University--lipoatrophy following long-term antiretroviral therapyDemetre Daskalakis
Division of Infectious Disease and Immunology, Department of Medicine, New York University School of Medicine/Bellevue Hospital, New York, NY, USA
MedGenMed 7:9. 2005
- Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047Carl J Fichtenbaum
University of Cincinnati College of Medicine, Holmes Hospital, Eden Avenue and Albert Sabin Way, Cincinnati, Ohio 45267-0405, USA
AIDS 16:569-77. 2002..Dose adjustment of pravastatin may be necessary with concomitant use of RTV and SQVsgc. Pravastatin does not alter the NFV pharmacokinetics, and thus appears to be safe for concomitant use...
- Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186John G Gerber
Department of Medicine, University of Colorado Health Sciences Center, Denver, CO, USA
J Acquir Immune Defic Syndr 47:459-66. 2008..AIDS Clinical Trials Group A5186 examined the safety and efficacy of fish oil plus fenofibrate in subjects not achieving serum TG levels < or =200 mg/dL with either agent alone...
- Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087Scott R Evans
Harvard School of Public Health, Boston, MA, USA
HIV Clin Trials 8:45-52. 2007..Triglyceride (TG) levels >400 mg/dL interfere with the accurate determination of low-density lipoproteins (LDL-C) by the Friedewald equation, making it difficult to assess coronary heart disease risk...
- Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trialDonald I Abrams
University of California, San Francisco, and Gladstone Institute of Virology and Immunology, San Francisco, California 94110, USA
Ann Intern Med 139:258-66. 2003..CONCLUSIONS: Smoked and oral cannabinoids did not seem to be unsafe in people with HIV infection with respect to HIV RNA levels, CD4+ and CD8+ cell counts, or protease inhibitor levels over a 21-day treatment...
- Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based reviewJudith A Aberg
Department of Medicine, New York University Medical Center, USA
Top HIV Med 14:134-9. 2006..The article is based on a presentation on management of dyslipidemia and other cardiovascular risk factors in HIV infection made by Judith A. Aberg, MD, at the International AIDS Society-USA Los Angeles CME program in February 2006...
- Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant womenSalome N Juethner
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri 63108, USA
J Acquir Immune Defic Syndr 32:153-6. 2003....
- Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 StudyJohn G Gerber
University of Colorado Health Sciences Center, Denver, CO 80262, USA
J Acquir Immune Defic Syndr 39:307-12. 2005..The reduced inhibition of HMG-CoA reductase activity during coadministration of EFV may result in diminished antilipid efficacy at usual doses of SIM, ATR, and PRA...
- Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitorsCarla B Washington
Department of Medicine, Stanford University Medical Center, Stanford, CA 94305-5130, USA
Clin Pharmacol Ther 73:406-16. 2003..The persistent effect of ritonavir suggests the possibility that lower doses and longer dosing intervals might be effective when ritonavir is used to boost concentrations of other protease inhibitors...
- Cardiovascular risk among HIV-positive patients on antiretroviral therapyJudith A Aberg
Division of Infectious Diseases School of Medicine, Washington University, St. Louis, Missouri, USA
J Int Assoc Physicians AIDS Care (Chic Ill) 2:S24-39. 2003..The fundamental message still is that physicians must treat HIV infection first. The choice of ART depends on many patient-specific factors, of which cardiovascular risk is only one...
- Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational studyCristina Mussini
Clinic of Infectious and Tropical Diseases, University of Modena and Reggio Emilia, Azienda Policlinico, Modena, Italy
Clin Infect Dis 38:565-71. 2004..Recurrent cryptococcal infection should be suspected in patients whose serum cryptococcal antigen test results revert back to positive after discontinuation of maintenance therapy...
- Cure of acute hepatitis C in HIV co-infection?Maria B Ristig
J Clin Gastroenterol 38:303. 2004
- Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapyMitchell Goldman
Division of Infectious Diseases, Indiana University School of Medicine, Wishard Memorial Hospital, Indianapolis, Indiana 46202, USA
Clin Infect Dis 38:1485-9. 2004....
- Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failedMaria B Ristig
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri 63108, USA
J Infect Dis 186:1844-7. 2002..There was a transient increase of transaminases after the initiation of treatment. No patient developed HBe antibodies. TDF is a very promising drug for the treatment of chronic hepatitis B in HIV-infected individuals...
- Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult Michael P Dube
Indiana University, Indianapolis, USA
Clin Infect Dis 37:613-27. 2003
- Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitisRobert A Larsen
Department of Medicine Infectious Diseases, 2020 Zonal Ave, IRD Room 632, MC 9520, University of Southern California, Los Angeles, CA 90033, USA
Antimicrob Agents Chemother 49:952-8. 2005..The half-life of MAb 18B7 in serum was approximately 53 h, while the MAb was undetectable in the cerebrospinal fluid of all patients. These data support the continued investigation of MAb 18B7 at a maximum single dose of 1.0 mg/kg...
- A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study TeamJudith A Aberg
Department of Medicine, Division of Infectious Disease, University of California San Francisco, San Francisco, CA, USA
J Infect Dis 187:1046-52. 2003..44/100 person-years (95% confidence interval, 0.04-8.01). Withdrawal of anti-MAC therapy appears to be safe in patients who have been treated with a macrolide-based regimen for at least 1 year and have an immunologic response on HAART...
- Clinical impact of patient population differences and genomic variation in efavirenz therapyJennifer King
AIDS 22:1709-17. 2008....
- Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV sheddingJacob P Lalezari
Quest Clinical Research, San Francisco, California, USA
Antimicrob Agents Chemother 46:2969-76. 2002..9 to 3.7 log(10) PFU/ml among the four regimens evaluated for anti-HCMV activity. 1263W94 was generally well tolerated; taste disturbance was the most frequently reported adverse event over the 28-day dosing period...
- Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuseSalome N Juethner
Division of Infectious Disease, Washington University School of Medicine, St Louis, Missouri 63108, USA
HIV Clin Trials 4:145-9. 2003....
- Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected personsEdgar Turner Overton
Washington University School of Medicine, St Louis, MO 63110, USA
Clin Infect Dis 41:1045-8. 2005..5%) developed a protective antibody response. In a logistic regression model, only a plasma HIV RNA level of <400 copies/mL at the time of vaccination was associated with a protective antibody response (P=.003)...
- Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148Michael P Dube
Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
Antivir Ther 11:1081-9. 2006..Dyslipidaemia is very common in patients with HIV infection, but current therapies are often suboptimal. Since niacin may cause insulin resistance and hepatotoxicity, it has generally been avoided in this setting...
- Dyslipidemia in HIV patientsMarisa Tungsiripat
Department of Infectious Diseases, The Cleveland Clinic Foundation, OH 44195, USA
Cleve Clin J Med 72:1113-20. 2005..Interactions between lipid-lowering drugs and antiretroviral drugs require special attention...
- Discontinuation of antiretroviral therapy postpartum: no evidence for altered viral set pointMarisa Tungsiripat
J Acquir Immune Defic Syndr 44:116-7. 2007
- New York University HIV/AIDS Clinical Trial UnitJudith Aberg; Fiscal Year: 2007..Our unit has given significant scientific contributions to the concept and design of many studies and will continue to do so. ADMINISTRATIVE COMPONENT: ..